STOCKHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2011

Preferred Stock and Common Stockholders' equity narrative [Abstract]

Stockholders' equity

10.           STOCKHOLDERS' EQUITY

Components of Comprehensive Income

The market valuation adjustment for the six months ended June 30, 2011 and 2010 represents unrealized holding (losses) gains on available-for-sale securities, net of taxes.  The net deferred loss on cash flow hedges for the six months ended June 30, 2011 and 2010 represents deferred losses on the Company's interest rate related derivative financial instruments designated as cash flow hedges, net of amounts reclassified to interest expense (see Note 9).  Foreign currency translation adjustments are not adjusted for income taxes since they relate to indefinite investments in non-U.S. subsidiaries.

Comprehensive Income

For the three months ended June 30, 2011 and 2010, comprehensive income was $165 million and $169 million, respectively.

Dividend Program

During each of the quarters of 2011 and 2010, the Company's Board of Directors has declared a quarterly cash dividend of $0.10 per common share.

Share Repurchase Plan

In January 2011, the Company's Board of Directors authorized the Company to repurchase an additional $750 million of the Company's common stock, increasing the total available authorization at that time to $1 billion.  The share repurchase authorization has no set expiration or termination date.

For the six months ended June 30, 2011, the Company repurchased 15.4 million shares of its common stock from SB Holdings Capital Inc., a wholly-owned subsidiary of GlaxoSmithKline plc., at an average price of $54.30 per share for a total of $835 million.  For the three and six months ended June 30, 2011, the Company reissued 1.1 million shares and 2.4 million shares, respectively, for employee benefit plans.  At June 30, 2011, $165 million remained available under the Company's share repurchase authorizations.

For the three months ended June 30, 2010, the Company repurchased 3.3 million shares of its common stock at an average price of $53.36 per share for a total of $175 million.  For the six months ended June 30, 2010, the Company repurchased 7.7 million shares of its common stock at an average price of $55.00 per share for $426 million, including 4.5 million shares purchased in the first quarter at an average price per share of $56.21 for $251 million under an accelerated share repurchase transaction ("ASR") with a bank.

Under the ASR, in January 2010, the Company repurchased 4.5 million shares of the Company's outstanding common stock for an initial purchase price of $56.05 per share.  The purchase price of these shares was subject to an adjustment based on the volume weighted average price of the Company's common stock during a period following execution of the agreement.  The total cost of the initial purchase was $250 million.  The purchase price adjustment was settled in the first quarter of 2010 and resulted in an additional cash payment of $0.7 million, for a final purchase price of $251 million, or $56.21 per share. 

  For the three and six months ended June 30, 2010, the Company reissued 0.6 million shares and 1.6 million shares, respectively, for employee benefit plans.